The Level of Antibodies to Tumor-Associated Glycans in Gastric Cancer Patients Is Lower than in Healthy Donors and Reduces with Age
Maxim P. Nikulin, Alexander D. Lipatnikov, Alexei Yu. Nokel, Svetlana M. Polyakova, Svetlana V. Tsygankova, Galina V. Pazynina, Alexandra V. Semyanikhina, Elena V. Ogorodnikova, Dmitry V. Rogozhin, Olesya M. Rossomakhina, Dmitrii A. Atiakshin, Olga I. Patsap, Ivan S. Stilidi
TL;DR
Gastric cancer patients have lower levels of antibodies against tumor-related sugars compared to healthy people, and these levels decrease with age.
Contribution
The study shows reduced anti-glycan IgM levels in gastric cancer patients, suggesting a potential immunodeficiency linked to tumor development.
Findings
Anti-glycan IgM levels decrease with age in both gastric cancer patients and healthy donors.
Gastric cancer patients have significantly lower IgM levels against most glycans compared to healthy donors.
Anti-GalNAcα antibodies bind to tumor cells and non-tumor cells in the same organ.
Abstract
A key function of naturally occurring antibodies is to control pathologically altered cells, such as those with aberrant glycosylation. Age-related diminution in the pool of B cells producing these immunoglobulins is linked to impaired anti-tumor immunity. In this study, the levels of antibodies against tumor-associated carbohydrate antigens (TACAs)—common in gastric cancer (GC) and other malignancies—were analyzed in 235 treatment-naïve GC patients (stages I–IV) and 76 healthy donors using a printed glycan array (PGA). We found that anti-glycan IgM levels, but not IgG, reduced with age in both patients and donors. Crucially, IgM levels against most glycans were significantly lower in the GC cohort compared with healthy donors, a trend that remained after age adjustment. Furthermore, an immunohistochemical analysis revealed that human anti-GalNAcα (Tn) antibodies—a well-characterized…
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Click any figure to enlarge with its caption.
Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7
Figure 8
Figure 9
Figure 10
Figure 11
Figure 12
Figure 13
Figure 14
Figure 15
Figure 16
Figure 17
Figure 18
Figure 19
Figure 20
Figure 21
Figure 22
Figure 23
Figure 24
Figure 25Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsGlycosylation and Glycoproteins Research · Monoclonal and Polyclonal Antibodies Research · Immunotherapy and Immune Responses